A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of haematology"
DOI: 10.1111/bjh.18887
Abstract: NPM1-mutated acute myeloid leukaemia (NPM1mut AML) represents a mostly favourable/intermediate risk disease that benefits from allogeneic haematopoietic stem cell transplantation (HSCT) in case of measurable residual disease (MRD) relapse or persistence after induction chemotherapy. Although… read more here.
Keywords: mutated acute; npm1 mutated; acute myeloid; molecular failure ... See more keywords